Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study

Heinz Ludwig, Carsten Bokemeyer, Matti Aapro, Mario Boccadoro, Pere Gascón, Kris Denhaerynck, Andriy Krendyukov, Ivo L Abraham, Karen Macdonald

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Aim: This study aimed to report patterns of biosimilar filgrastim prophylaxis and outcomes of chemotherapy-induced neutropenia (CIN)/febrile neutropenia (FN) in patients with hematological malignancies or solid tumors. Patients & methods: MONITOR-GCSF is a real-world study of 1447 cancer patients receiving CIN/FN prophylaxis with biosimilar filgrastim (solid tumors: 77.2%; hematological malignancies: 22.8%). Results: Differences in prophylaxis intensity and day of initiation relative to guideline recommendations were observed. In hematology patients, higher rates of CIN and FN occurred at cycle level, and rate of FN was higher at patient level (9.1 vs 5.0% in solid tumor patients). Conclusion: Adequate GCSF support in hematology and solid tumor patients is important to prevent CIN/FN and related hospitalizations and chemotherapy disturbances.

Original languageEnglish (US)
Pages (from-to)897-907
Number of pages11
JournalFuture Oncology
Volume15
Issue number8
DOIs
StatePublished - Mar 1 2019

Fingerprint

Biosimilar Pharmaceuticals
Febrile Neutropenia
Hematologic Neoplasms
Neutropenia
Drug Therapy
Neoplasms
Hematology
Filgrastim
Hospitalization

Keywords

  • biosimilar
  • filgrastim
  • granulocyte colony-stimulating factor
  • hematological malignancies
  • neutropenia
  • solid tumors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies : MONITOR-GCSF study. / Ludwig, Heinz; Bokemeyer, Carsten; Aapro, Matti; Boccadoro, Mario; Gascón, Pere; Denhaerynck, Kris; Krendyukov, Andriy; Abraham, Ivo L; Macdonald, Karen.

In: Future Oncology, Vol. 15, No. 8, 01.03.2019, p. 897-907.

Research output: Contribution to journalArticle

Ludwig, Heinz ; Bokemeyer, Carsten ; Aapro, Matti ; Boccadoro, Mario ; Gascón, Pere ; Denhaerynck, Kris ; Krendyukov, Andriy ; Abraham, Ivo L ; Macdonald, Karen. / Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies : MONITOR-GCSF study. In: Future Oncology. 2019 ; Vol. 15, No. 8. pp. 897-907.
@article{198af20a5bf44a43a08f48fa8ff37662,
title = "Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study",
abstract = "Aim: This study aimed to report patterns of biosimilar filgrastim prophylaxis and outcomes of chemotherapy-induced neutropenia (CIN)/febrile neutropenia (FN) in patients with hematological malignancies or solid tumors. Patients & methods: MONITOR-GCSF is a real-world study of 1447 cancer patients receiving CIN/FN prophylaxis with biosimilar filgrastim (solid tumors: 77.2{\%}; hematological malignancies: 22.8{\%}). Results: Differences in prophylaxis intensity and day of initiation relative to guideline recommendations were observed. In hematology patients, higher rates of CIN and FN occurred at cycle level, and rate of FN was higher at patient level (9.1 vs 5.0{\%} in solid tumor patients). Conclusion: Adequate GCSF support in hematology and solid tumor patients is important to prevent CIN/FN and related hospitalizations and chemotherapy disturbances.",
keywords = "biosimilar, filgrastim, granulocyte colony-stimulating factor, hematological malignancies, neutropenia, solid tumors",
author = "Heinz Ludwig and Carsten Bokemeyer and Matti Aapro and Mario Boccadoro and Pere Gasc{\'o}n and Kris Denhaerynck and Andriy Krendyukov and Abraham, {Ivo L} and Karen Macdonald",
year = "2019",
month = "3",
day = "1",
doi = "10.2217/fon-2018-0814",
language = "English (US)",
volume = "15",
pages = "897--907",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "8",

}

TY - JOUR

T1 - Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies

T2 - MONITOR-GCSF study

AU - Ludwig, Heinz

AU - Bokemeyer, Carsten

AU - Aapro, Matti

AU - Boccadoro, Mario

AU - Gascón, Pere

AU - Denhaerynck, Kris

AU - Krendyukov, Andriy

AU - Abraham, Ivo L

AU - Macdonald, Karen

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Aim: This study aimed to report patterns of biosimilar filgrastim prophylaxis and outcomes of chemotherapy-induced neutropenia (CIN)/febrile neutropenia (FN) in patients with hematological malignancies or solid tumors. Patients & methods: MONITOR-GCSF is a real-world study of 1447 cancer patients receiving CIN/FN prophylaxis with biosimilar filgrastim (solid tumors: 77.2%; hematological malignancies: 22.8%). Results: Differences in prophylaxis intensity and day of initiation relative to guideline recommendations were observed. In hematology patients, higher rates of CIN and FN occurred at cycle level, and rate of FN was higher at patient level (9.1 vs 5.0% in solid tumor patients). Conclusion: Adequate GCSF support in hematology and solid tumor patients is important to prevent CIN/FN and related hospitalizations and chemotherapy disturbances.

AB - Aim: This study aimed to report patterns of biosimilar filgrastim prophylaxis and outcomes of chemotherapy-induced neutropenia (CIN)/febrile neutropenia (FN) in patients with hematological malignancies or solid tumors. Patients & methods: MONITOR-GCSF is a real-world study of 1447 cancer patients receiving CIN/FN prophylaxis with biosimilar filgrastim (solid tumors: 77.2%; hematological malignancies: 22.8%). Results: Differences in prophylaxis intensity and day of initiation relative to guideline recommendations were observed. In hematology patients, higher rates of CIN and FN occurred at cycle level, and rate of FN was higher at patient level (9.1 vs 5.0% in solid tumor patients). Conclusion: Adequate GCSF support in hematology and solid tumor patients is important to prevent CIN/FN and related hospitalizations and chemotherapy disturbances.

KW - biosimilar

KW - filgrastim

KW - granulocyte colony-stimulating factor

KW - hematological malignancies

KW - neutropenia

KW - solid tumors

UR - http://www.scopus.com/inward/record.url?scp=85062849749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062849749&partnerID=8YFLogxK

U2 - 10.2217/fon-2018-0814

DO - 10.2217/fon-2018-0814

M3 - Article

C2 - 30827127

AN - SCOPUS:85062849749

VL - 15

SP - 897

EP - 907

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 8

ER -